Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

• ClinicalTrials.gov Identifier: NCT03317405
• Recruitment Status: Active, not recruiting
• First Posted: October 23, 2017
• Last Update Posted: March 9, 2022
• Sponsor: National Cancer Institute (NCI)
• Information provided by (Responsible Party): National Cancer Institute (NCI)

Tracking Information

• First Submitted Date: October 20, 2017
• First Posted Date: October 23, 2017
• Last Update Posted Date: March 9, 2022
• Actual Study Start Date: October 31, 2018
• Actual Primary Completion Date: February 22, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 20, 2017)

Incidence of skin toxicity [ Time Frame: Up to 60 days ]

Will be assessed by Common Terminology Criteria for Adverse Events version 4.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: February 17, 2022)

• Drug concentration [ Time Frame: Up to 60 days ]
  Will be assessed in breast tissue and blood.
• Breast tissue biomarkers [ Time Frame: Up to 60 days ]
  Ki67 labeling index, progesterone receptor and estrogen receptor expression, and expression of a panel of genes reported to change with Z-endoxifen hydrochloride (ENX) exposure, will be measured in breast tissue samples obtained at diagnostic core needle biopsy performed prior to study entry, and compared to the measurements in post-therapy surgical samples.
• Coagulation proteins [ Time Frame: Up to 60 days ]
  Will assess coagulation proteins measures of systemic estrogenicity in plasma.
• Treatment related symptoms [ Time Frame: Up to 60 days ]
  Assessed using the Behavioral and Emotional Screening System questionnaire. Average, median and range of scores for each noted group will be provided as descriptive measures of location and variance.

Original Secondary Outcome Measures (submitted: October 20, 2017)

• Breast tissue biomarkers [ Time Frame: Up to 60 days ]
  Ki67 labeling index, progesterone receptor and estrogen receptor expression, and expression of a panel of genes reported to change with Z-endoxifen hydrochloride (ENX) exposure, will be measured in breast tissue samples obtained at diagnostic core needle biopsy (CNB) performed prior to study entry, and compared to the measurements in post-therapy surgical samples.
• Coagulation proteins [ Time Frame: Up to 60 days ]
  Will assess coagulation proteins measures of systemic estrogenicity in plasma.
• Drug concentration [ Time Frame: Up to 60 days ]
  Will be assessed in breast tissue and blood.
• Drug metabolism genes [ Time Frame: Up to 60 days ]
  Will study drug metabolism genes in germline deoxyribonucleic acid (DNA) from peripheral blood (buffy coat) for DNA/ribonucleic acid (RNA) isolation.
• Plasma hormone levels for steroid hormones [ Time Frame: Up to 60 days ]
  Will be measured by liquid chromatography (LC)/mass spectrometer (MS)/MS.

Current Other Pre-specified Outcome Measures (submitted: February 17, 2022)

Tissue biologic response [ Time Frame: Up to 60 days ]

Will be compared as pre- and post-therapy values, to explore the potential therapeutic effects of the two doses of ENX. A nonparametric test of the central parameter being zero will be performed.

• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
• Official Title: Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
• Brief Summary: This randomized phase I trial studies the side effects and best dose of endoxifen hydrochloride in treating participants who are undergoing breast surgery. Endoxifen hydrochloride may treat or reduce the risk of breast cancer.

Detailed Description

PRIMARY OBJECTIVE:

I. To establish the dermal tolerability and safety of endoxifen hydrochloride (endoxifen [ENX]) gel administered topically to both breasts at two doses: 10 mg daily (5 mg per breast) and 20 mg daily (10 mg per breast) in comparison to vehicle placebo gel, using objective assessments based on Common Terminology Criteria for Adverse Events (CTCAE) criteria.

SECONDARY OBJECTIVES:

I. To measure the breast tissue concentrations of (E) and (Z) isomers of N-desmethyl-4-hydroxytamoxifen (ENX) and 4-hydroxytamoxifen (4-OHT) at each dose (10 mg per day and 20 mg per day).

II. To measure the plasma concentrations of (E) and (Z) isomers ENX and 4-OHT at each dose (10 mg per day and 20 mg per day).

III. To measure serum estrogenic response to topical ENX gel therapy in comparison to vehicle placebo gel (sex hormone binding globulin and insulin-like growth factor [IGF] pathway proteins).

IV. To assess changes in coagulation parameters (factor VIII, factor IX, vWF, protein S) in response to ENX gel therapy in comparison to vehicle placebo gel.

V. To assess symptoms related to use of endoxifen gel in comparison to vehicle placebo gel, as assessed by the Breast Cancer Prevention Trial (BCPT) Eight Symptom Scale (BESS) questionnaire.

EXPLORATORY OBJECTIVE:

I. Using pathological lesion-matched pre- and post-therapy tissue samples, to explore the potential therapeutic effects of the two doses of ENX gel in comparison to vehicle placebo gel: a) by IHC, Ki67 labelling (for cell proliferation), estrogen receptor (ER), progesterone receptor (PR) expression (for estrogen blockade); b) by expression of a panel of genes reported to change with ENX exposure (using nanostring assays).

OUTLINE: Participants are randomized in Cohorts 1 and 2. All subjects in Cohort 3 will receive active agent.

COHORT I: Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.

COHORT II: Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.

COHORT III: Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.

After completion of study treatment, participants are followed up at 60 days.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Prevention

Condition

• Breast Ductal Carcinoma In Situ
• Breast Lobular Carcinoma In Situ
• Stage 0 Breast Cancer AJCC v6 and v7
• Stage I Breast Cancer AJCC v7
• Stage IA Breast Cancer AJCC v7
• Stage IB Breast Cancer AJCC v7
• Stage II Breast Cancer AJCC v6 and v7
• Stage IIA Breast Cancer AJCC v6 and v7
• Stage IIB Breast Cancer AJCC v6 and v7
• Stage III Breast Cancer AJCC v7
• Stage IIIA Breast Cancer AJCC v7
• Stage IIIB Breast Cancer AJCC v7
• Stage IIIC Breast Cancer AJCC v7

Intervention

• Drug: Endoxifen Hydrochloride
  Apply to the skin
  Other Names:

  • Z-Endoxifen HCl
  • Z-Endoxifen Hydrochloride
• Other: Placebo Administration
  Apply to the skin
• Other: Questionnaire Administration
  Ancillary studies

Study Arms

• Experimental: Cohort I (endoxifen hydrochloride)
  Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
  Interventions:

  • Drug: Endoxifen Hydrochloride
  • Other: Questionnaire Administration
• Placebo Comparator: Cohort II (placebo)
  Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
  Interventions:

  • Other: Placebo Administration
  • Other: Questionnaire Administration

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: March 19, 2021): 33
• Original Estimated Enrollment (submitted: October 20, 2017): 38
• Estimated Study Completion Date: February 22, 2023
• Actual Primary Completion Date: February 22, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Women scheduled for unilateral or bilateral mastectomy for breast cancer therapy, pathology confirmed stage 0-III (including ductal carcinoma in situ), or prophylaxis (BRCA1/2 mutation carriers, women with strong family history or lobular carcinoma in situ or other conditions where prophylactic mastectomy has been elected)
• Age >= 18 years (since breast cancer is not a pediatric disease and no safety data are available for ENX use in children)
• Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
• Total bilirubin < 1.5 x upper limit of normal (ULN) (in women with prior documented bilirubin elevations consistent with Gilbert's syndrome, total bilirubin up to 3 x ULN will be allowed)
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) < 2.5 x ULN
• Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x ULN
• Creatinine < 2 x ULN
• Alkaline phosphatase < 2.5 x ULN
• Blood urea nitrogen < 2 x ULN
• Ability to understand and the willingness to sign a written informed consent document which includes a requirement to apply study agent to sensitive body parts daily
• Willingness and ability to schedule mastectomy 21-28 days following start of study agent; women with breast implants may participate
• Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of study agent dosing
• Negative urine or serum pregnancy test result, for participants of child bearing potential; female of child-bearing potential is any woman (regardless of sexual orientation, whether she has undergone a tubal ligation, or remains celibate by choice) who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; AND has had a menstrual period at any time in the preceding 12 consecutive months)
• The effects of topical ENX gel on the developing human fetus are unknown; for this reason, women of child-bearing potential and their male partners must agree to use effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

Exclusion Criteria:

• The presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Paget's disease is permitted
• Women receiving a "nipple delay" procedure prior to mastectomy
• Women with skin diseases (psoriasis, eczema)
• A history of thromboembolic disorder
• Endometrial intraepithelial neoplasia (also known as atypical hyperplasia) or a high risk of uterine cancer, defined here as known carriers of Lynch syndrome mutations (MLH1, MSH2, MSH6, PMS2)
• Participants may not have received any other investigational agents in the previous 3 months
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen
• Taken tamoxifen or other selective estrogen/progesterone receptor modulators (SERMs/SPRMs) within two years prior to entering study or been required to discontinue SERM therapy due to thromboembolic or uterine toxicity
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• History of prior breast cancer-specific therapy within the previous 2 years (chemotherapy, radiation, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors); previous unilateral radiation of the contralateral side in women scheduled for mastectomy is allowed; study gel will be applied to both breasts
• History of prior mastectomy
• Pregnant or breastfeeding
• Patients receiving neoadjuvant chemotherapy with curative intent
• Men are excluded from this study since breast cancer is men is rare and there are no data regarding skin penetration of topical breast cancer prevention agents through male chest wall skin (which is thicker and harrier than female chest wall skin)
• Current users of other topical medications on the breast skin must be willing and able to discontinue use for the duration of participation; body lotion and other non-medicinal topical compounds may be applied > 4 hours after study gel application

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03317405
• Other Study ID Numbers: NCI-2017-01921; NCI-2017-01921 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); N01-CN-2012-00035; NCI2017-09-01 ( Other Identifier: Northwestern University ); NWU2017-09-01 ( Other Identifier: DCP ); N01CN00035 ( U.S. NIH Grant/Contract ); P30CA060553 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: National Cancer Institute (NCI)
• Original Responsible Party: Same as current
• Current Study Sponsor: National Cancer Institute (NCI)
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Seema A Khan; Northwestern University

• PRS Account: National Cancer Institute (NCI)
• Verification Date: February 2022